EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis

Jens Blobner, Laura Dengler, Constantin Eberle, Julika J Herold, Tao Xu, Alexander Beck, Anton Mühlbauer, Katharina J Müller, Nico Teske, Philipp Karschnia, Dominic van den Heuvel, Ferdinand Schallerer und 8 weitere

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03837-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Jens Blobner und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, LMU University Hospital, Ludwig Maximilians University (LMU), 81377, Munich, Germany. Hauptthemen laut MEDLINE: Brain Neoplasms, Programmed Cell Death 1 Receptor, Lung Neoplasms, Immunotherapy, Adoptive. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marie Sklodowska-Curie Training Network for Optimizing Adoptive T Cell Therapy of Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancer brain metastasis has a devastating prognosis, necessitating innovative treatment strategies. While chimeric antigen receptor (CAR) T-cell show promise in hematologic malignancies, their efficacy in solid tumors, including brain metastasis, is limited by the immunosuppressive tumor environment. The PD-L1/PD-1 pathway inhibits CAR T-cell activity in the tumor microenvironment, presenting a potential target to enhance therapeutic efficacy. This study aims to evaluate the impact of anti-PD-1 antibodies on CAR T-cell in treating lung cancer brain metastasis.

Methods

We utilized a murine immunocompetent, syngeneic orthotopic cerebral metastasis model for repetitive intracerebral two-photon laser scanning microscopy, enabling in vivo characterization of red fluorescent tumor cells and CAR T-cell at a single-cell level over time. Red fluorescent EpCAM-transduced Lewis lung carcinoma cells ( EpCAM/tdt LL/2 cells) were implanted intracranially. Following the formation of brain metastasis, EpCAM-directed CAR T-cell were injected into adjacent brain tissue, and animals received either anti-PD-1 or an isotype control.

Results

Compared to controls receiving T-cell lacking a CAR, mice receiving EpCAM-directed CAR T-cell showed higher intratumoral CAR T-cell densities in the beginning after intraparenchymal injection. This finding was accompanied with reduced tumor growth and translated into a survival benefit. Additional anti-PD-1 treatment, however, did not affect intratumoral CAR T-cell persistence nor tumor growth and thereby did not provide an additional therapeutic effect.

Conclusion

CAR T-cell therapy for brain malignancies appears promising. However, additional anti-PD-1 treatment did not enhance intratumoral CAR T-cell persistence or effector function, highlighting the need for novel strategies to improve CAR T-cell therapy in solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsProgrammed Cell Death 1 ReceptorLung NeoplasmsImmunotherapy, AdoptiveEpithelial Cell Adhesion MoleculeReceptors, Chimeric AntigenAnimalsMiceHumansImmune Checkpoint InhibitorsMice, Inbred C57BLCell Line, TumorCarcinoma, Lewis LungFemaleT-LymphocytesTumor Microenvironment

Stichwörter der Autor:innen

Brain metastasisCAR T cellLung cancerPD-1-blockade

Substanzen

Programmed Cell Death 1 ReceptorEpithelial Cell Adhesion MoleculeReceptors, Chimeric AntigenImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Neurosurgery, LMU University Hospital, Ludwig Maximilians University (LMU), 81377, Munich, Germany.
  • German Cancer Consortium (DKTK), Partner Site Munich, A Partnership Between the DKFZ Heidelberg and the University Hospital of the LMU, Munich, Germany.
  • Division of Neuro-Oncology, Department of Neurosurgery, Ludwig Maximilians University School of Medicine, Marchioninistrasse 15, 81377, Munich, Germany.
  • Department of Neurology, LMU University Hospital, Ludwig Maximilians University (LMU), 81377, Munich, Germany.
  • Center for Neuropathology and Prion Research, Faculty of Medicine LMU Munich, Ludwig-Maximilians-University (LMU), Munich, Germany.
  • Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675, Munich, Germany.

Förderung

  • Marie Sklodowska-Curie Training Network for Optimizing Adoptive T Cell Therapy of Cancer

Zitieren

APA

Blobner, J., Dengler, L., Eberle, C., Herold, J. J., Xu, T., Beck, A., Mühlbauer, A., Müller, K. J., Teske, N., Karschnia, P., van den Heuvel, D., Schallerer, F., Ishikawa-Ankerhold, H., Thon, N., Tonn, J. C., Subklewe, M., Kobold, S., Harter, P. N., Buchholz, V. R., & von Baumgarten, L. (2024). PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03837-9

Vancouver

Blobner J, Dengler L, Eberle C, Herold JJ, Xu T, Beck A, et al. PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03837-9

BibTeX
@article{Blobner2024,
  author = {Blobner, Jens and Dengler, Laura and Eberle, Constantin and Herold, Julika J and Xu, Tao and Beck, Alexander and Mühlbauer, Anton and Müller, Katharina J and Teske, Nico and Karschnia, Philipp and van den Heuvel, Dominic and Schallerer, Ferdinand and Ishikawa-Ankerhold, Hellen and Thon, Niklas and Tonn, Joerg-Christian and Subklewe, Marion and Kobold, Sebastian and Harter, Patrick N and Buchholz, Veit R and von Baumgarten, Louisa},
  title = {PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03837-9}
}
Kostenlos starten →